Renishaw投资D3 Technologies公司

目前本页还没有简体中文版。您可以使用Google的翻译服务查阅 自动翻译。 我们不负责提供该项服务,而且翻译结果未经过我们的检查。
如果您需要更多帮助,请 联络我们

网页内容下载致电当地的办事处 在线联系我们

Renishaw is pleased to announce it has acquired a 75% interest in D3 Technologies Limited ("D3"), a company set up in collaboration with the University of Strathclyde and others to exploit certain patents related to Surface Enhanced Raman Spectroscopy ("SERS") and to develop SERS for molecular diagnostics and trace detection.

Renishaw’s investment in D3 will comprise cash of £1.85 million and instrumentation, with a combined value of approximately £5m over the next 5 years.

Part of the investment has been used by D3 to purchase for £850,000 the business and assets of the analytical business unit ("ABU") operated by Mesophotonics Limited, a spin-out company from the University of Southampton. The ABU develops and manufactures substrates used in SERS applications.

Combining the SERS technology and biochemistry expertise of the University of Strathclyde with the Klarite© substrate technology of Mesophotonics ABU offers a broad range of product opportunities to exploit in the growing healthcare diagnostics and forensic markets.

As a leading supplier of Raman instrumentation Renishaw has a vested interest in the furtherance of Raman spectroscopy and its applications into new and developing markets.

Renishaw’s principal business is the design, manufacture and sale of advanced precision metrology and inspection equipment and analytical systems. Over 90% of its sales are exported internationally through its world-wide network of subsidiaries and distributors. Renishaw’s sales for the financial year ended 30 June 2006 were £175.8m.

News updates

Register for regular news updates from Renishaw

All images and text - copyright Renishaw

后续步骤

如果您需要了解更多信息或者询价, 或有其他要求,可以直接联络当地的Renishaw办事处